Home › Funds › Caligan Partners LP › SGMT
Caligan Partners LP position in SGMT
SAGIMET BIOSCIENCES INC · Health Care
Caligan Partners LP reported holding 2,794,484 shares of SGMT (SAGIMET BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$27.6M, representing 1.69% of its reported portfolio and ranking #18 among its reported holdings. Caligan Partners LP has disclosed SGMT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Caligan Partners LP's SGMT position evolved
Caligan Partners LP first disclosed a stake in SGMT in Q2 2026 at 2,500,000 shares (US$19.3M). The position peaked in Q3 2026 at 2,794,484 shares, worth US$27.6M. Across 2 filings, Caligan Partners LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,794,484 shares valued at US$27.6M — an increase of 294,484 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 2.50M | $19.32M | New |
| Q3 2026 | 2.79M | $27.61M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SGMT and 13F data
SGMT (SAGIMET BIOSCIENCES INC) is a Health Care company. 61 other funds we track also report a position in SGMT — the largest reported positions include SILVERARC CAPITAL MANAGEMENT, LLC (US$37.0M), BVF INC/IL (US$34.6M), Commodore Capital LP (US$27.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SGMT
- SILVERARC CAPITAL MANAGEMENT, LLC 3.75M sh · $37.01M · Q3 2026
- BVF INC/IL 3.50M sh · $34.58M · Q3 2026
- Commodore Capital LP 2.76M sh · $27.25M · Q3 2026
- Affinity Asset Advisors, LLC 2.53M sh · $24.97M · Q3 2026
- Saturn V Capital Management LP 2.00M sh · $19.79M · Q3 2026
- GREAT POINT PARTNERS LLC 1.96M sh · $19.38M · Q3 2026
- Spruce Street Capital LP 1.40M sh · $13.83M · Q3 2026
- Atom Investors LP 725.92K sh · $7.17M · Q3 2026
- Jones Hill Capital LP 502.59K sh · $4.97M · Q3 2026
- Seven Fleet Capital Management LP 429.11K sh · $4.24M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 423.01K sh · $4.18M · Q3 2026
- Palo Alto Investors LP 250.00K sh · $2.47M · Q3 2026
More on Caligan Partners LP
FAQ
How long has Caligan Partners LP held SGMT?
Caligan Partners LP has disclosed SGMT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Caligan Partners LP's current position in SGMT?
As of Q3 2026, Caligan Partners LP holds 2.79M shares of SGMT (SAGIMET BIOSCIENCES INC), valued at $27.61M, representing 1.69% of its reported portfolio and ranking #18.
Has Caligan Partners LP been buying or selling SGMT?
In the latest 13F filing (Q3 2026), Caligan Partners LP increased its position in SGMT. The position peaked in Q3 2026 at 2.79M shares.
Which other funds hold SGMT?
Other major institutional holders of SGMT include SILVERARC CAPITAL MANAGEMENT, LLC, BVF INC/IL, Commodore Capital LP, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.